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Abstract 
Background: Several antipsychotic agents are known to prolong the QT interval in a 
dose dependent manner.  Corrected QT interval (QTc) exceeding a threshold value of 
450 ms may be associated with an increased risk of life threatening arrhythmias.  
Antipsychotic agents are often given in combination with other psychotropic drugs, such 
as antidepressants, that may also contribute to QT prolongation.  This observational 
study compares the effects observed on QT interval between antipsychotic 
monotherapy and psychoactive polytherapy, which included an additional 
antidepressant or lithium treatment. 
Method: We examined two groups of hospitalized women with Schizophrenia, Bipolar 
Disorder and Schizoaffective Disorder in a naturalistic setting. Group 1 was composed 
of nineteen hospitalized women treated with antipsychotic monotherapy (either 
haloperidol, olanzapine, risperidone or clozapine) and Group 2 was composed of 
nineteen hospitalized women treated with an antipsychotic (either haloperidol, 
olanzapine, risperidone or quetiapine) with an additional antidepressant (citalopram, 
escitalopram, sertraline, paroxetine, fluvoxamine, mirtazapine, venlafaxine or 
clomipramine) or lithium.  An Electrocardiogram (ECG) was carried out before the 
beginning of the treatment for both groups and at a second time after four days of 
therapy at full dosage, when blood was also drawn for determination of serum levels of 
the antipsychotic. 
Results: Mean QTc intervals significantly increased in Group 2 (24 ± 21 ms) however 
this was not the case in Group 1 (-1 ± 30 ms) (Repeated measures ANOVA p<0,01). 
Furthermore we found a significant difference in the number of patients who exceeded 
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the threshold of borderline QTc interval value (450 ms) between the two groups, with 
seven patients in Group 2 (38%) compared to one patient in Group 1 (7%) (Fisher Exact 
Text, p<0,05).  
Conclusions: No significant prolongation of the QT interval was found following 
monotherapy with an antipsychotic agent, while combination of these drugs with 
antidepressants caused a significant QT prolongation.  Careful monitoring of the QT 
interval is suggested in patients taking a combined treatment of antipsychotic and 
antidepressant agents.  
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Introduction 
The QTc interval is a heart rate corrected value that measures the time between the 
onset and the end of electrical ventricular activity.  Prolongation of this interval is 
considered a marker of the arrhythmogenic potential of a drug specifically linked to an 
increased risk of torsade de pointes ventricular tachycardia [1]. 
According to a document presented by the Committee for Proprietary Medicinal 
Products (CPMP) in 1997, normal subjects can be divided into three groups based on 
QTc interval length.  For males, QTc values less than 430 ms are normal, between 431 
and 450 ms are borderline and over 450 ms are prolonged.  Whereas for females QTc 
values less than 450 ms are normal, between 451 and 470 ms are borderline and over 
470 ms are prolonged. 
In this document it was also suggested that individual changes of QTc length of 
between 30 and 60 ms from baseline raises concern for the potential risk of drug 
induced arrhythmias [2]. 
Antipsychotics such as thioridazine, ziprasidone, quetiapine, risperidone, olanzapine or 
haloperidol have been suggested to prolong QTc interval [3, 4, 5, 6]. 
Some authors reported that antidepressant drugs, including Selective Serotonine 
Reuptake Inhibitors (SSRI) (fluvoxamine, paroxetine and sertraline), Tricyclic 
Antidepressants (TCA) (amytriptiline, clomipramine, imipramine), and lithium can also 
prolong QTc interval [7, 8, 9].   
Almost all drugs causing significant QT prolongation are known to interact with 
repolarizing potassium channels, particularly with the rapid component of delayed 
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rectifier potassium currents (Ikr), encoded by the human Ether-a-go-go related gene 
(HERG) [10]. 
However, TCA agents may affect the QTc interval primarily by their effect on sodium 
channels during depolarization [11].  Nonetheless TCA can also affect HERG potassium 
channels [12]. 
Drug trapping and structure-function studies suggest that the inner cavity of HERG 
channels is larger than other voltage-gated potassium channels and is therefore able to 
accommodate diverse chemical structures [13].  Among those drugs there are also 
SSRI like fluvoxamine [14], citalopram [15] and fluoxetine [16]. 
The combination of antipsychotic and antidepressant agents seems to have addictive 
effects on QTc interval [17]. 
We investigated the effects of polypharmacy on QTc in two groups of psychiatric female 
inpatients. Our null hypothesis was that patients treated with antipsychotics plus 
antidepressants or lithium would not have a greater QTc prolongation, if any, than 
patients treated with antipsychotics alone. 
Methods 
A prospective naturalistic observational study was conducted in the Department of 
Psychiatry of San Matteo Hospital in Pavia. The study was approved by local Ethics 
Review Committee.  
We chosed to recruit only women because of their higher risk of developing drug related 
arrythmias [18].  Consecutive  female inpatients admitted from August 2003 to April 
2004, with schizophrenia, bipolar disorder or schizoaffective disorder, were considered 
eligible for the study. Diagnoses were made by two staff psychiatrists (one attending 
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and one resident psychiatrist), after reaching a clinical consensus in accordance to the 
DSM IV. 
Pharmacological and medical history were obtained. 
Included patients had to be free from psychiatric medications for at least 48 hours if they 
were taking antidepressant or antipsychotics like velafaxine, risperidone, haloperidol, 
paroxetine, that have an half life inferior to 20 hours. Patients taking drugs with a longer 
half life, like citalopram or fluoxetine, had to be free from psychiatic medication for at 
least two times the half life of the drug they were taking. Patients treated with depot 
preparations were excluded. Non psychoactive drugs, like cardiovascular drugs, were 
allowed only if they were not reported to alter QT interval.  
Patients with disturbances of cardiac rate and rhythm, history of prolonged QTc, QTc 
interval greater than 470 ms in the ECG performed at admission, alterations of hepatic 
or renal function were also excluded.   
For each subject, therapy was started according to the clinical evaluation of psychiatrist 
in charge of the patient. The first group (Group 1) included women who were treated 
with only an antipsychotic (concomitant benzotropine treatment was permitted, as also 
zolpidem for insomnia was),  the second group (Group 2) was composed of female 
patients who started treatment with antipsychotics in association with either an 
antidepressant or lithium.  The dosage equivalent of haloperidol was calculated [19].  
Two ECGs were obtained for each patient, the first before the beginning of treatment 
and the second after four days of treatment with the patients on the full therapeutic daily 
dose of antipsychotic prescribed by the clinician, generally after one week from the 
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beginning of the treatment, except for the patients treated with clozapine, who had the 
second ECG four days after the end of titration (generally after two weeks of therapy).  
On the same day of the first ECG, blood samples were drawn for the evaluation of 
potassium serum levels from all the participants.  When the second ECG was 
administered, blood was drawn to obtain potassium and additionally magnesium serum 
levels as well as serum levels of the antipsychotic agent.  
Samples for plasmatic levels determination were drawn before the first drug dose in the 
morning. Serum antipsychotic levels were analyzed by high-performance liquid 
chromatography with ultraviolet detection. 
The ECGs were obtained by standard 3-leads resting ECG procedure in the supine 
position and analyzed by a resident cardiologist (A. V.) who was blind to the patient’s 
condition, study hypothesis, treatment status, serum levels of antipsychotics and was 
not involved in patient care.  The QTc interval was calculated with the Bazzett formula.  
The QT interval was assessed in both DII and V2 leads.  It was decided to focus on DII 
leads measurements due to the higher variability of measurements in precordial leads. 
A repeated measures analysis of variance was used to test the effect of treatments on 
QTc (within subject factor: time of ECG examination, between subject factor: therapy 
group).  Fisher Exact Test  was used to compared the number of patients who exceed 
the threshold of borderline QTc values in Group 1 and Group 2. Indipendent  T-Sample 
Tests were used to test the differences between baseline QTc values, ages and 
duration of illness using the statistical package Stata 7.0 (Stata Coorporation, 2001).  
Results 
Patients’ characteristics 
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Our sample consisted of thirty eight women.   Ninenteen  were included in the Group 1 
and ninenteen in the Group 2.  
Age and duration of illness were comparable between the two groups (Table 1). 
Data on diagnosis and previous pharmacological treatment of patients are reported in 
Table 1. 
Among the nineteen patients in Group 1, five were treated with haloperidol, five with 
olanzapine, five with risperidone and four with clozapine; among the nineteen patients 
of group 2, five started haloperidol, eight olanzapine, four risperidone and two 
quetiapine.  Antidepressant used were escitalopram (two patients), citalopram (three 
patients), mirtazapine (four patients), paroxetine (one patients), sertraline (two), 
fluvoxamine (one patient), venlafaxine (three patients), clomipramine (two patients). 
Three patients started also lithium treatment. 
The mean antipsychotic doses, equivalent doses and mean plasmatic levels are 
reported in (Table 2).  Potassium and magnesium serum levels were always within the 
normal range for all subjects.  
QTc interval 
Mean baseline QTc intervals were similar in the two groups: 422 ± 26 ms in group 1 and 
414 ± 22 ms in group 2 (Indipendent T-test p>0,5).  One patient in the monotherapy 
group, who started clozapine treatment,  was excluded from this analysis and from  pre-
post treatment comparisons because QTc in DII was not measurable with sufficient 
accuracy.  
Three patients in the first group had QTc values that exceeded 450 ms at baseline while 
no patients in Group 2 exceeded this threshold before starting treatment.  
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The average QTc interval after treatment was 421±20 ms in the monotherapy group 
(range 391-452) and 438± 30 and in the polytherapy group (range 379-488) 
(Indipendent T test, p<0,05). 
Compared with the baseline, mean QTc change after treatment was – 1 ±  30 ms in 
Group 1 and 24 ± 21 ms in Group 2 (repeated measures ANOVA p<0,05). 
After treatment only one patient in Group 1 reached the threshold for borderline values 
of QTc interval in comparison to seven patients in Group 2 (Fisher Exact Text p<0,05). 
Moreover, in Group 2 two patients had a QTc exceeding 470 ms.  
The highest prolongations of QTc intervals (66 ms and 55 ms) were found in two 
patients taking risperidone, the first in association to clomipramine and the second in 
association to escitalopram.  However in these two cases plasmatic dosages of 
antipsychotics were not higher than in other patients who reported a shorter QTc 
prolongation. 
 Discussion 
We found that the psychiatric population treated with antipsychotic monotherapy had 
much less risk of developing an increase in QTc interval compared to those treated with 
antipsychotics plus an antidepressant or lithium.  
Two main mechanisms seem to operate in determining the prolongation of QTc interval 
during treatment with different combinations of psychoactive drugs.  The first is the 
synergic blockade of the HERG potassium channels, the second is the increase in drug 
levels (with subsequent augmented risk of cardiotoxicity) due to metabolic interactions 
between drugs that share the same metabolic pathway [20]. This mechanism may be 
   11
particularly relevant in subject with genetic-determined impairment of CYP2D6 and 
CYP3A4 drug-metabolizing enzymes (poor metabolizer subjects) [21].   
In our study, metabolic interactions leading to  abnormal elevation of serum levels of 
antipsychotics did not seem to be the principal determinant of the greater QTc 
prolongation in the group with combined therapy.  Indeed serum levels of antipsychotics 
were all within or under the expected range after therapeutic dosing in both groups, they 
were not higher in Group 2 compared to Group 1 and the highest prolongations 
observed were not associated with the highest antipsychotic serum levels. 
Recently, Harringan et al [22] analyzed, in a prospective randomized study, the effects 
of six antipsychotics on the QTc interval; they found that each of the antipsychotics 
were associated with measurable QTc prolongation which was not augmented by 
concomitant use of metabolic inhibitors, even if in their study plasmatic levels of 
antipsychotics raised after the addition of the specific metabolic inhibitor.  
In our study, the combination of different drugs doesn’t seem to cause strong 
interactions on drug metabolism. However, in our sample, the combination of drugs that 
specifically interfere in their own methabolism, like fluvoxamine and olanzapine, 
paroxetine and risperidone, were avoided by clinicians. 
 Antidepressant used in our study have a mild inhibitory action on antipsychotic 
methabolism and this can explain why antipsychotic serum levels didn’t raise in Group 2 
compared to Group 1. It is reassuring to find that significant pharmacokinetic 
interactions do not occur when the antipsychotics studied were coadministered with 
antidepressant commonly used in clinical practice. 
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If the metabolic interactions do not seem to be the most important explanation for our 
results, an alternative explanation might be the synergic actions of different drugs on ion 
channels.  
The two patients with the highest prolongations were both taking risperidone, which is 
noted to block the I kr current [ 23, 24].  Actually, many psychotropic drugs share this 
capacity to inhibit Ikr current, including not only antipsychotic agents but also 
antidepressant agents like citalopram, fluoxetine, paroxetine [15, 23].  Those agents 
may have synergic effect when used in combination.  
This study has several limitations, most of them related to the naturalistic setting of this 
study: we chosed to administer the second ECG after four days of therapy at full dosage 
(generally after one week from recruitment) because all antipsychotic used reached the 
steady-state in 3-5 days.  Actually we couldn’t chose a longer interval between the first 
and the second ECG because the average duration of recovery in our ward is 8,5 days. 
Dosing was clinically determined for symptom response by the treating psychiatrist and 
hence, doses varied within and between groups. Moreover statistical comparison of 
QTc interval changes among agents was not possible because of the small number of 
the samples. 
Finally we didn’t measure antidepressant serum levels.  Consistently with data reported 
in literature, we thought that antipsychotic would have been the principal drugs involved 
in QTc prolongation, while antidepressant would have only a role of potentiating agents.  
Actually, serum levels of antidepressants would have helped to explain the greater 
prolongation observed in Group 2. 
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Conclusions 
Prolongation of the QT interval by a non cardiovascular drug including notably an 
antipsychotic agent is considered a good marker of the arrythmogenic potential of that 
agent [1].  
Psychiatric patients had been identified as a population at risk for cardiovascular 
problems [11, 25].  Mortality rates are higher in psychiatric patients than in the general 
population [26] and the pharmacological treatment itself might produce side effects that 
affect mortality from causes other than suicide [27].  
There is a vast amount of evidence available showing the effect of a single 
antipsychotic on QTc interval however there is not much evidence obtained for clinical 
populations treated with a different combinations of drugs. 
Interestingly, the response to repolarization prolonging stimuli is “patient-specific” [8]. 
Thus, detecting the patients with a reduced repolarization reserve [28,29] will lead to 
personalized psychotropic therapy according to the predisposition of that patient to 
develop cardiac side effects with a certain drug. 
In view of the fact that psychiatric patients are considered high risk subjects and since 
they frequently show electrolytes unbalances [30], an accurate monitoring of the QTc 
interval before and after the beginning of treatment appears warranted, particularly for 
patients taking multiple psychoactive drugs, sharing QTc prolonging properties.  
Further observational studies on larger samples of patients, comparing QTc intervals, 
plasmatic levels of antipsychotics and daily doses of psychotropic drugs are necessary 
to perform statistical comparisons for each kind of antipsychotic and for each kind of 
antipsychotic-antidepressant association commonly used in clinical practice. 
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Table I.  Diagnosis, duration of illness, psychoactive treatment before recruitment and age of 
patients 
  
Diagnosis 
 
Comorbid 
Disorders 
(N) 
 
Duration 
of illness 
(yr) 
 
Psychoactive 
treatment 48 
hours before 
recruitment (N) 
 
Age (yr) 
Mean ± 
SD 
 
Age (yr) 
Range 
 
Group 1 
Patients in 
monotherapy 
 
Schiz 17 
Schizoaf 2 
 
0 
 
 
5,8± 5 
 
Haloperidol 3 
Risperidone 2 
  
 
 
45,7± 15 
 
 
 
22-77 
 
Group 2 
Patients in 
politherapy 
 
Schizoaf 
10 
Bip Dis  3 
Schiz  6 
 
An Nervosa 
2 
Alc Abuse 2  
 
 
4,2± 3 
 Venlafaxine 2 
  Haloperidol 1 
  Risperidone 2 
Atenolole 2 
Lacipidine 1 
Amlodipine 1 
Ranitidine 1 
 
 
45,79± 
12,8 
 
 
26-74 
Schizoaf: Schizoaffective Disorder; Schiz: Schizophrenia; Bip Dis: Bipolar Disorder; An 
Nervosa: Anorexia Nervosa; Alc Abuse: Alcohol Abuse yr: years
  
Table 2. Mean oral daily dose , plasmatic levels and equivalent dose of antipsychotics in the group of patients receiving 
monotherapy and in the group receiving polytherapy 
   Patients with monotherapy 
Group 1 
Patients with polytherapy 
Group 2 
antips antips 
CYP 450 
pathway 
Therap serum 
levels (ng/ml) 
n. 
pts 
mean dose 
(mg/die) 
mean 
serum 
level 
(ng/ml) 
Mean 
hal 
equivalent 
dose 
(mg/die) 
n. 
pts 
mean dose 
(mg/die) 
mean 
serum 
level 
(ng/ml) 
mean  
hal 
equivalent 
dose 
(mg/die) 
antidep 
used 
(n. pts) 
antidep 
CYP 450 
pathway 
 
hal CYP3A4 
CYP2D6 
 
 
5-15 ng/ml 
 
5 
4,8 ± 2 3,9 ± 2 4,8 
 
5 
4±1 3,54± 1 3 
Cit 2 
Mir 1 
Lit 1 
    Ser1 
 
CYP2D6 
CYP3A4 
CYP1A2 
 
ola 
CYP1A2 
 
 
10-100 ng/ml 
 
5 
14 ± 5 
38,4 ± 
16 
10,5 
 
8 
9±5 41,8 ± 28 6,5 
Ven 3 
Mir 2 
Par 1 
Ser 1 
   Cit 1 
 
CYP2D6 
CYP3A4 
CYP1A2 
risp 
CYP2D6 
  
6- 70 ng/ml 
(ris+9Ohrisp) 
 
5 
3 ± 1 
29,4 ± 
21 
6 
 
4 
3 ± 2 26,3 ± 12 6,8 
Clom 2 
Escit 1 
Fluv 1 
 
CYP2D6 
CYP3A4 
CYP1A2 
clo 
CYP1A2 
CYP3A4 
 
200-1200 ng/ml 
(clo+Nor clo) 
 
4 317 ± 
144 
593 ± 
243 
9 
 
- - - - 
 
- 
 
 
que 
CYP3A4 
 
140-365 ng/ml 
 
- 
- - - 
 
2 400 ± 
283 
55 ± 21 10,7 
Esc+Lit 1 
Mir+Lit 1 
CYP2D6 
CYP3A4 
CYP1A2 
Hal : haloperidole, ola: olanzapine; clo: clozapine; Nor clo: nor-clozapine; que: quetiapine; risp: risperidone; 9OH risp: 
idrossiriseridone; mir: mirtazapine; cit: citalopram; esc:escitalopram; ser:sertraline; ven:venlafaxine; clom: clomipramine; 
par: paroxetine; lit: lithium; pts: patients; antid: antidepressant; antips: antipsychotic.
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Figure 1. Mean QTc (bars indicate standard deviations) values at baseline (T0) and 
after four days at full dosage (T1)  of antipsychotic therapy, in the monotherapy (1) and 
politherapy (2) groups. 
